Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

@article{Neuvonen2006DrugIW,
  title={Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance},
  author={P. Neuvonen and M. Niemi and J. Backman},
  journal={Clinical Pharmacology & Therapeutics},
  year={2006},
  volume={80}
}
  • P. Neuvonen, M. Niemi, J. Backman
  • Published 2006
  • Medicine
  • Clinical Pharmacology & Therapeutics
  • Lipid‐lowering drugs, especially 3‐hydroxy‐3‐methylglutaryl–coenzyme A inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic disease. The benefits of statins are well documented. However, lipid‐lowering drugs may cause myopathy, even rhabdomyolysis, the risk of which is increased by certain interactions. Simvastatin, lovastatin, and atorvastatin are metabolized by cytochrome P450 (CYP) 3A4 (simvastatin acid is also metabolized by CYP2C8); their plasma… CONTINUE READING
    671 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Cardiovascular disease is the leading cause of mortality after renal transplantation, accounting for more than 30% of deaths. Elevated lipid levels (hyperlipidemia) are a frequent… Expand
    ConditionsHyperlipidemias
    InterventionDrug
    Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers
    • 15
    Drug–drug interactions that interfere with statin metabolism
    • 43
    • Highly Influenced
    Statin Muscle Toxicity and Genetic Risk Factors
    • 3
    • PDF
    An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
    Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    • 105
    Drug–drug interaction with statins
    • 23
    An updated review of interactions of statins with antibacterial and antifungal agents
    • 3
    • PDF

    References

    SHOWING 1-10 OF 173 REFERENCES
    Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
    • 802
    • PDF
    Clinical Pharmacokinetics of Fluvastatin
    • 150
    Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors
    • 91